Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

Tango Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of precision oncology therapies. The company leverages synthetic lethality and genetic ...
AOL

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?

Transaction value is based on the SEC Form 4 weighted average purchase price ($10.15), while post-transaction value is calculated using the market close price on October 23, 2025. The 477,401 shares ...
Investing

Tango Therapeutics stock hits 52-week high at $13.47

Tango Therapeutics Inc. (TNGX) stock reached a new 52-week high of $13.47, marking a significant milestone for the biotechnology company. This achievement reflects a remarkable 1-year change, with the ...
ETF Daily News

Bank of New York Mellon Corp Reduces Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Bank of New York Mellon Corp lessened its holdings in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) by 7.8% during the 4th quarter, HoldingsChannel reports. The fund owned 103,020 ...
Investing

Tango Therapeutics stock hits 52-week high at $17.64

Tango Therapeutics Inc (TNGX) has reached a new 52-week high, with its stock price climbing to $17.64. This milestone marks a significant achievement for the company, reflecting a robust performance ...